ArticleHematology, transfusion and cell therapy2026
Comparative analysis of low- and high-dose apheresis platelets in platelet-refractory patients with hematologic malignancies.
Article in Hematology, transfusion and cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlloimmunization-induced platelet transfusion refractoriness represents a major clinical challenge in hematology-oncology. Optimal strategies for platelet support in this population remain to be established.
objectiveThis study aimed to compare the efficacy of low-dose crossmatched versus high-dose uncrossmatched single donor apheresis platelets (SDAP) in platelet-refractory patients with hematologic malignancies by assessing corrected count increment (CCI), percent platelet recovery (PPR), and post-transfusion platelet increment (PPI). MATERIALS AND
methodsForty alloimmunized, platelet-refractory patients were enrolled. Solid phase red cell adherence assay was used for crossmatching and alloimmunization detection. Patients received low-dose crossmatched SDAP (1.49 ± 0.30 × 10
resultsThe CCI and PPR% were significantly higher following low-dose crossmatched SDAP compared to standard-dose SDAP (p-value <0.05). Compared to high-dose uncrossmatched SDAP, low-dose crossmatched SDAP produced slightly higher CCI and PPR%, but differences were not statistically significant (p-value = 0.27). PPI was significantly higher with high-dose uncrossmatched SDAP (p-value <0.01) compared with low-dose crossmatched SDAP. Transfusion intervals and bleeding episodes were similar across both groups.
conclusionLow-dose crossmatched SDAP achieves comparable efficacy to high-dose uncrossmatched SDAP in refractory, alloimmunized patients with hematologic malignancies. These results support low-dose crossmatched SDAP as a feasible strategy to optimize transfusion support, minimize complications, and improve hemostasis management in refractory patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.